ABOS:NSD-Acumen Pharmaceuticals Inc. Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.81

Change

-0.32 (-3.94)%

Market Cap

USD 0.31B

Volume

0.08M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Acumen Pharmaceuticals Inc. Common Stock (ABOS) Stock Analysis:
Based on the Acumen Pharmaceuticals Inc. Common Stock stock forecasts from 4 analysts, the average analyst target price for Acumen Pharmaceuticals Inc. Common Stock is not available over the next 12 months. Acumen Pharmaceuticals Inc. Common Stock’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acumen Pharmaceuticals Inc. Common Stock is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Acumen Pharmaceuticals Inc. Common Stock’s stock price was USD 7.81. Acumen Pharmaceuticals Inc. Common Stock’s stock price has changed by -0.46 % over the past week, -6.61 % over the past month and +0.00 % over the last year.

About

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+5.23 (+1.73%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

+10.57 (+3.17%)

USD87.92B 10.55 8.07
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.18%)

USD67.82B 10.14 7.73
VRTX Vertex Pharmaceuticals Incorpo..

-0.64 (-0.31%)

USD48.34B 24.52 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-31.73 (-9.17%)

USD33.38B N/A N/A
SGEN Seagen Inc

-7.93 (-5.00%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.80%)

USD25.21B 56.53 6.26
ALNY Alnylam Pharmaceuticals Inc

-11.49 (-6.28%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ABOS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.31B 53% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.41 82% B- 70% C-
Price / Cash Flow Ratio -41.18 89% B+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 52.73% 94% A 96% A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 15.75 7% F 3% F
Short Percent 2.25% 72% C- 55% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector